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Abstract
Thierry Heidmann wins the 2009 Retrovirology prize.
In 2005, thanks to the generosity of the Ming K. Jeang
Foundation, the Retrovirology  prize was inaugurated. A
goal of the Retrovirology Prize is to identify an outstanding
mid-career scientist who is close to the peak of his/her
productivity and who is expected to have many future
years of high achievement. Previous winners of the Retro-
virology Prize include Stephen Goff [1], Joseph Sodroski
[2], Karen Beemon [3] and Ben Berkhout [4].
For 2009, the Editors of Retrovirology have selected Thierry
Heidmann (Figure 1) as the recipient of the Retrovirology
Prize.
TH heads a CNRS laboratory at Université Paris-Sud and
Institut Gustave Roussy in Villejuif, in the southern sub-
urbs of Paris. With a strong background in physics and
mathematics, he was interested in the early 1980's in link-
ing these disciplines of science with biology, more pre-
cisely with neurobiology and the science of complex
neuronal networks. To fulfil his aspiration, Thierry
entered Jean-Pierre Changeux's lab at the Pasteur Institute
to start a PhD on the newly discovered acetylcholine
receptor. This exciting experience led Thierry to turn to
more applied science, following a profound will to slowly
but surely shift from studying the physical sciences to
studying the biological sciences! After his PhD, Thierry
focused on transposable elements and retrotransposons.
The question he asked at that time was simple: how to be
able to monitor the transposition of these mobile ele-
ments in a mammal where genetic approaches to detect
transposition were both poorly efficient and time con-
suming. He then decided to devise a system that could
detect retrotransposition of any element whose mobiliza-
tion includes a reverse transcription step, no matter where
the reverse transcribed, transposed element would target
and integrate. This search resulted in 1988 in the genera-
tion of the first indicator gene for retrotransposition. This
was his first step in the field, but a decisive one. Since
then, his laboratory has focused on three complementary
directions: the regulation of retroelements' activities, the
search for functional endogenous retroviruses, and their
role in physiological and pathological conditions.
Professor Ali Saib, a member of the editorial board of Ret-
rovirology  http://www.Retrovirology.com asked him a
series of questions on these elements and about his views
on several issues raised by his investigations.
AS: Before becoming interested in endogenous 
retroviruses, you studied neurobiology. What 
did you work on?
TH: In fact, I followed a rather atypical path. I attended the
"École Normale Supérieure" in Paris where I learned phys-
ics and mathematics. Initially, I was thinking about astro-
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physics, but I rapidly became interested in the multiple
attempts, that at that time were already very popular, to
make a link between these domains of science and that of
biology, and more precisely with neurobiology and the
science of complex neuronal networks. Therefore, I rap-
idly looked for laboratories dedicated to biology that had
a special interest in these aspects of science, and I was very
happy to find a very open-minded scientist, who was able
both to think about receptor-ligand interactions at the
molecular level and to build models for neuronal net-
works and integrated thinking processes, in the person of
Jean-Pierre Changeux, at the Pasteur Institute. So in the
course of the ENS program, I entered Jean-Pierre
Changeux's lab and started PhD work on the newly dis-
covered and still very mysterious acetylcholine receptor.
My approach was initially that of a physicist, and I man-
aged to identify the rapid allosteric transitions that proved
to be associated with the binding of acetylcholine to its
receptor, and resulting in the opening of the ion channel.
A step further was achieved with the characterization of
the receptor-associated channel, which proved to be made
of the central space generated by the pentameric arrange-
ment of the receptor, and that we managed to label in its
closed and open states by constructing an apparatus
allowing both the rapid addition of acetylcholine to the
receptor, that of a non-competitive blocker of the ion
channel and the real-time labeling of the latter by milli-
second UV irradiation of the complex. A comprehensive
allosteric model for neurotransmitter action as initially
postulated by Jean-Pierre Changeux was therefore con-
firmed. These biochemical and physico-chemical studies
also led us to propose a model for the regulation of syn-
aptic efficacy, based on the unexpected observation that
the receptor could exist under two conformations in
reversible equilibrium. So that was my first experience in
Biology.
AS: In choosing a new research direction, why 
did you focus on endogenous retroviruses and 
not on HIV, which was much more in the lime 
light. It was a difficult choice in France, or even 
internationally, where this topic wasn't (and still 
isn't) very developed?
TH: After my PhD on this rather theoretical work in
molecular neurobiology, I decided to turn to more
applied science, following a profound willingness to
slowly but surely shift from physical to medical sciences
and   cope with human diseases. So I began to think about
tumors, in relation with transposable elements, retro-
transposons, and retroviruses, being aware that in several
species where genetics had been a powerful tool such as
Drosophila and mice, it was clear that a large fraction of
the observed mutations (eye pigmentation in Drosophila,
fur color in mice) were associated with insertional muta-
genesis, mediated by mobile elements. At that time, a very
illuminating paper had just been published by Boeke et al.
in Cell, showing that the Ty element in yeast was a retro-
transposon, i.e. an element that requires a reverse tran-
scription step to replicate, in a strictly intracellular
process, thus incredibly resembling the replicative cycle of
retroviruses, although the latter have an extracellular life
cycle. A minireview by Baltimore also in Cell had very
nicely stressed these similarities. So it could be envisioned
that what oncogenic retroviruses can do simply by sto-
chastic insertion into the host genome, maybe endog-
enous elements could also do it, provided that they are
transcriptionally active. And the first question that I asked
was simple: how to monitor the mobility of these ele-
ments in a mammal where genetic approaches to detect
transposition were both inefficient and long-drawn-out?
Indeed, only a fraction of the insertional events are
expected to result in a mutation associated with a detecta-
ble phenotypic trait, and therefore I decided to design a
system that could detect retrotransposition of any element
mobilized by a process involving a reverse transcription
step, whatever the target and integration site of the reverse
transcribed, transposed element. This search led in 1988
to the generation of the first « indicator gene for retro-
transposition » [5] a device which included a marker gene
(neomycin resistance or lacZ) interrupted by an intronic
sequence that inactivates the marker gene in its initial
form and which is eliminated in the course of processing
of the transitory « RNA » intermediate of the retrotranspo-
Thierry Heidmann Figure 1
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son, with the transposed element hence expressing the
marker gene. This indicator gene in its various forms is
now widely used by all labs working on retroelements and
actually proved to be extremely powerful, both in vitro and
in vivo, to characterize the mechanism of transposition of
retroelements, and to study the regulation mechanisms
that nature has imposed on them so that they do not
wreak genomic havoc. That was the way I entered the ret-
rovirology field!
AS: Was it difficult to make such a shift?
TH: In fact not at all! I have to say that I could take advan-
tage of the French system for academic research, which
gave me the opportunity to propose a new research pro-
gram just after my PhD. Although it was not very classical,
I did not make a « true » post-doc but I started immedi-
ately my new project. At the beginning, I was doing
molecular biology in Jean-Pierre Changeux's lab, who
kindly let me start on a totally non-neurobiological
project (!), and I was doing cell culture and retrovirology
with Jean-François Nicolas in François Jacob's lab, that
was located just one floor below. This period lasted a few
months, and it was really a wonderful time; and then I
searched for a lab in the field and I rather naturally turn to
Jean-Bernard LePecq who was at the time director of a
CNRS unit at the Institut Gustave Roussy, and who pro-
vided me with a small lab in the newly constructed
Research Department. The Institut Gustave Roussy is
devoted to cancer research, and was interested in my pro-
posed research program, that actually they have always
supported, together with the CNRS all along these years.
So I was not at that time focused on HIV, and the scientific
authorities from whom I was dependent were in fact inter-
ested in tumor biology. Maybe I should add that my atyp-
ical formation, my strong determination to explore the
new field of retroelements and endogenous retroviruses,
and the relative freedom allowed within our academic
research system, were sufficient arguments to let me go.
AS: What are the most important advances to 
which you contributed?
TH: Actually, the first element that I investigated for its
possible retrotransposition was a simple retrovirus, the
mouse leukemia virus (MLV), whose env gene we deleted
and replaced with the indicator gene for retrotransposi-
tion. And we could demonstrate that it was able to retro-
transpose intracellularly, thus clearly showing the very
close link that exists between retroviruses and retrotrans-
posons. This « principal » paper also depicted a clear-cut
method for quantitative measurement of retrotransposi-
tion frequency of a given element in a given cell line (as
straightforward as for bacteria using the Luria & Delbruck
or the Newcombe methods). This initial demonstration
was followed by several others, including the demonstra-
tion and follow-up of the retrotransposition of a mouse
IAP sequence that we had marked and which proved to
retrotranspose very efficiently in a tumor cell line [6], and
the demonstration that the LINE elements, i.e. non-LTR
retrotransposons, also retrotranspose, as do Alu
sequences, the human prototypic representative member
of the non-coding SINEs. For the LINEs, we did not hesi-
tate to turn to Drosophila where a functional LINE ele-
ment -the I element- had been identified and cloned by
Bucheton's group, and which could be mobilized by
appropriate crosses between Drosophila contaminated by
this element and Drosophila still free of the element. This
element was marked by a neoR-containing indicator gene
for retrotransposition; the element was introduced by
transgenesis into Drosophila; and retrotransposition was
followed by direct selection of the offspring by introduc-
ing the selecting drug directly into the food on which the
larva thrived. And remarkably, some Drosophila were
found to perfectly survive on this otherwise « lethal » food;
the DNA of these survivors was analyzed, and indeed a
transposed copy of the transgene was in each case identi-
fied, with the intron precisely spliced out, thus demon-
strating unambiguously retrotransposition of LINEs, that
had taken place in the mother germline. This work was
extended about 5 years later by Kazazian's group working
on human LINEs, using a functional LINE that they had
identified and cloned from a patient where such an ele-
ment had recently transposed. LINE were also demon-
strated by our group to be involved in the generation of
the so-called processed pseudogenes: these are in general
non-functional copies of bona fide genes, but which lack
introns, end with a polyA stretch, and lack a promoter,
thus suggesting that they are most probably generated by
a reverse transcription process, from a gene transcript.
Again, thanks to the indicator gene of retrotransposition
that we used to mark classical genes, we could reconstitute
pseudogene formation in vitro, and further demonstrate
that LINEs were carrying out this process very efficiently
[7]. Not only LINEs were able to take charge of a gene
transcript, but we also showed that they were responsible
for the mobilization of SINE elements. These short and
highly abundant elements of the human and mouse
genome (more than a million copies) are mobile but non-
coding, and are synthesized as a highly structured tran-
script by RNA Polymerase III. The latter property led us to
devise a new indicator gene, in which the initial intronic
sequence was replaced by a self-splicing intron, that was
taken from Tetrahymena: this new indicator gene did not
impose the RNA Polymerase II-dependent spliceosome
pathway to be used by the marked retrotransposon, and
indeed allowed a clear demonstration -and follow-up- of
the retrotransposition of both the human Alu sequence,
and the mouse B1 and B2 SINE, as well as the identifica-
tion of the structural features of the RNA intermediate
responsible for the incredibly efficient retrotransposition
of these elements.Retrovirology 2009, 6:108 http://www.retrovirology.com/content/6/1/108
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AS: And what about ERVs?
TH: Our search for endogenous retroviruses (ERVs)
started well ahead of the time when genomes were
sequenced, and was based on the old observation -by elec-
tron microscopists- that virus-like particles can be
observed in the placenta and in some tumors. Accord-
ingly, we first searched for retrovirus-like sequences that
might be expressed, by using the classical tools of molec-
ular biology: RNA from freshly recovered placenta were
assayed for the presence of pol-containing sequences,
using RT-PCR with degenerate primers matching the
highly conserved RT domains in the pol gene. Doing so, a
class of endogenous retroviruses that were named HERV-
L was identified, which proved to be a very ancient acqui-
sition of animal genomes, before the radiation of mam-
mals, about 100 million years (My) ago. These elements
were found to be still active in the mouse where they had
been subjected to an amplification burst after the diver-
gence between mouse and rat, and to be responsible for
the formation of the epsilon particles that had been iden-
tified in 2-cell embryos by electron microscopists 40 years
ago and had remained orphan since then. In a way we
made a sort of viral archeology, over million years of evo-
lution.
Thanks to the progress in the sequencing of both the
human and mouse genomes, it became rapidly possible to
have a clear-cut view of the extent and impact of ERVs:
they occupy as much as 8% of these genomes, with signif-
icant differences between mice and humans. In the
mouse, an extensive characterization of the various fami-
lies of ERVs led to the identification of several families
among which we managed to identify fully functional
copies, still able to replicate, with in some cases the sur-
prising evidence that the number of remaining functional
copies was as low as unity, thus suggesting that some ERV
families can simply die out. A similar conclusion was actu-
ally derived from our ERV-L study, showing that survival
of an ERV family is actually dependent on the subtle bal-
ance between replication efficiency and genetic drift, with
the ability of a given element to make multiple functional
copies of itself being the sole parameter responsible for its
survival, independently of any selective pressure. Interest-
ingly, we identified a specific feature of the very successful
mouse ERVs, and especially of the IAP and MusD ele-
ments -which are responsible for the majority of the muta-
tions by insertion identified in the mouse: these ERVs
have acquired a strictly intracellular life cycle, at variance
with their retroviral « progenitor ». And we proposed that
this physical constraint, by preventing the dilution of the
viral particles in the extracellular medium, favors the
immediate integration of the replicating element within
the producing cell genome. Interestingly, the natural his-
tory of this evolutionary process, that we named « intrac-
ellularization », could be reconstituted at the molecular
level, and the nature of the viral progenitor of these ele-
ments even could be determined. For both elements we
could demonstrate that intracellularization was simply
due to mutations in the N-terminal domain of gag, which
led to a change in the addressing of the viral particle from
the cell membrane to either the cytoplasm or the mem-
brane of the endoplasmic reticulum. This intracellulariza-
tion resulted in degeneration of the env  gene, with an
envelope protein becoming useless for a particle no longer
exiting the cell. In one case, that of the IAP sequences, a
systematic search within the mouse genome led to the
unambiguous identification of the viral progenitor of
these intracellularized particles, with the identification of
a functional proviral copy -named IAP-E- that proved to
be able to generate fully infectious viral particles, budding
at the cell membrane, and that could be converted by
introducing the appropriate sequence at its gag N-termi-
nus into a strictly intracellular ERV, indistinguishable
from a bona fide IAP particle, being even able to efficiently
undergo retrotransposition. Again, with this specific
example, we could demonstrate the very intimate link
between infectious retroviruses and retroelements, with
the passage from one to the other, which had taken place
over million years of evolution, being recapitulated in the
laboratory.
AS: What about the Human ERVs?
TH: In the case of human ERVs, the situation proved to be
slightly different, since analysis of the human genome
revealed that most -if not all- the proviral copies that can
be identified are most probably defective for autonomous
replication, their gag, pol and env genes being disrupted by
stop codons, deletions and insertions. Yet, there is one
exception, that of the HERV-K family of endogenous ret-
roviruses, which displays human specific copies not
found in the chimpanzee, from which we could « resurrect
», for the first time, an infectious retrovirus -that we
named Phoenix- by constructing a proviral genome based
on a consensus sequence derived from the identified cop-
ies. A similarly active copy could also be obtained by
recombination of two proviral copies, thus strongly sug-
gesting that fully functional copies could possibly still be
present in some individuals. Yet, such alleles remain to be
found, and are actually searched for by several groups.
AS: So many retroelements, but what about 
genome stability?
TH: You are right, retroelements occupy as much as 45%
of the human or mouse genome, with 8% being ERVs. So
in parallel, during these years, our laboratory -as well as
others-has investigated the important issue of the regula-
tion of the activity of retroelements. To be relevant, we
carried out such studies essentially in vivo, using appropri-
ate animal models (Drosophila and mice) and transgene-
sis. Consistent with the expected deleterious effects ofRetrovirology 2009, 6:108 http://www.retrovirology.com/content/6/1/108
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insertional mutagenesis, a series of studies provided evi-
dence for highly restricted activity of retroelements, and
involvement of essential regulatory processes to « tame »
these elements. Among the most salient outcomes from
our laboratory, I would like to cite the in vivo demonstra-
tion of the restriction of the expression of IAP endogenous
retroviruses to the male germline, using lacZ-marked ele-
ments introduced by transgenesis, the involvement of
CpG-methylation in somatic restriction, and the evidence
for somatic demethylation and induction of expression
under specific conditions. In Drosophila, we could dem-
onstrate -via the introduction by transgenesis of small
non-coding fragments of the LINE I element- that I ele-
ment activity is restricted by an « homology-dependent
gene silencing » process, requiring transcripts from the
introduced I fragments for mediating inhibition by RNA
interference [8]. And finally, in collaboration with Olivier
Schwartz at the Pasteur Institute, we could demonstrate
the primary role of cellular APOBEC proteins in the tam-
ing of mammalian endogenous retroviruses, with the
effects of APOBEC expression being demonstrated ex vivo,
as well as in vivo through the analysis of the traces left in
the course of evolution by APOBEC enzymes on the series
of endogenous retroviruses that can be found in the
mouse and human genome. Again these last results illus-
trate the strong similarities between ERVs and infectious
RVs, with the APOBEC proteins having been initially dis-
covered via their inhibitory effects on infectious retrovi-
ruses, but finally having most probably been selected
million years ago to prevent genome invasion by retroele-
ments.
AS: ERVs could play a role not only via their 
mobility but also via expression of their proper 
genes; what about their env gene on which you 
have now focused most of your research?
TH: We rapidly focused on the retroviral envelope pro-
teins, and made a systematic search for full length, intact
env genes within the human genome. This search resulted
in the identification of a rather low number of elements,
with only 18 genes identified. Among them, 2 proved to
be very important, as they are able to mediate cell-cell
fusion ex vivo, are specifically expressed in the placenta,
and are conserved in primate evolution. Syncytin-1 was
discovered by two groups, one in the US and one in
France, and syncytin-2 by our group. It became rapidly
clear that these retroviral envelopes have been co-opted by
their host -more than 25 My ago- for a physiological func-
tion in relation with the formation of the syncytiotro-
phoblast layer at the materno-fetal interface. Our
laboratory has been involved in the characterization of
syncytin-2, the oldest syncytin found in all simians, with
the identification of its cognate receptor and evidence for
its possible involvement in the « in-fusion » of the mono-
nucleated cytotrophoblasts into the syncytiotrophoblast.
Yet, a definitive demonstration of the role of syncytins in
mammalian placentation was only recently obtained, via
the mouse model and the generation of knockout ani-
mals. To do so, we first searched for syncytin genes in the
mouse genome, and found two such genes that we named
syncytin-A and -B, which proved to be divergent from the
human syncytins and to correspond to totally independ-
ent « retroviral gene captures » by a rodent ancestor. These
two genes possess all the characteristic features of bona fide
syncytins, as they can mediate cell-cell fusion ex vivo, they
are specifically expressed in the placenta at the maternal-
fetal interface, and have been conserved over > 20 My of
evolution of rodents. Then, knockout mice for one of
these genes very simply provided evidence that syncytins
are indeed absolutely required for placentation, with evi-
dence for lack of syncytiotrophoblast formation, resulting
in embryo death at mid-gestation [9]. Work is now in
progress to determine whether syncytins can be found in
all placental mammals (and a series of preliminary data
are indicative that it is indeed the case), thus supporting
the working hypothesis that placental mammals may
have emerged via the capture of a primitive retroviral
envelope, possibly replaced in the course of evolution by
newly acquired and diverse envelopes such as those that
can be observed today.
AS: This is definite evidence for a positive effect 
of ERVs, but what about negative effects?
TH: One important outcome of the detailed study of ret-
roviral envelopes from both exogenous and endogenous
retroviruses was the demonstration that they possess an
immunosuppressive activity that can be revealed in an in
vivo assay based on the inhibition of tumor rejection by
the mouse immune system. Actually, we showed in a «
principal » paper [10] that tumor cells engrafted into
immunocompetent mice are no longer rejected if they
have been previously transduced by an expression vector
for a retroviral envelope. In this paper, we further sug-
gested that this property could be of importance for two
major processes: in viremia for bona fide infectious retro-
viruses, where immunosuppression by the env gene could
be essential for viral propagation in an immunocompe-
tent animal, and in tumors where endogenous retrovi-
ruses are currently activated, and where the expressed
endogenous envelopes could participate in tumor pro-
gression by inhibiting immunosurveillance. Consistent
with the second hypothesis, we could unambiguously
demonstrate that this is indeed the case, for mouse
tumours such as the B16 melanoma or the N2a neuroblas-
toma. Both tumors express endogenous retroviruses nor-
mally silent, and by using RNA interference we
demonstrated that knocking down these ERVs resulted in
the rejection of the tumor cells, with re-expression of the
sole ERV env gene reverting the effect. Adoptive transfer of
regulatory T cells restored tumour progression of theRetrovirology 2009, 6:108 http://www.retrovirology.com/content/6/1/108
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knocked-down tumor cells, indicating that they are key to
the ERV-mediated effect. These experiments strongly sug-
gested that induction of ERVs, a process currently
observed in tumors, including in humans, contributes to
escape from immunosurveillance, via the immunosup-
pressive activity carried by the associated envelope pro-
teins. Concerning the first hypothesis, on the impact of
the immunosuppressive activity of the envelope protein
of infectious retroviruses on viremia, recent experiments
also indicate that this activity is absolutely required for
productive infection in a mouse model, via inhibition of
the host immune system.
AS: Could this immunosuppressive activity play 
a role in the case of syncytins?
TH: A third hypothesis that we had not introduced in our
1998 PNAS paper concerns the syncytins: being env genes
from endogenous retroviruses, they are expected to be not
only fusogenic -in relation with syncytiotrophoblast for-
mation- but also immunosuppressive. This actually
proved to be the case, for at least one of them in both the
primate and rodent lineage, leading to the working
hypothesis that this property could play a role -or could
have played a role in evolution- in the establishment of
maternal-fetal tolerance, and even be associated with the
emergence of placental mammals from egg-laying ani-
mals. Actually, such a hypothesis still remains a working
model, and a series of experiments are underway in our
laboratory using for instance knocked-in mice in which
we have selectively abolished the immunosuppressive
activity of the syncytins without altering their fusogenic
activity, via specific mutations. Whatever the outcome of
these experiments, it is already clear that endogenous ret-
roviruses can no longer be considered simply as junk
DNA, with their demonstrated involvement in a physio-
logical process such as placentation.
AS: So you would conclude that viruses harm us 
as much as they help us. What do you think of 
this idea?
TH: Your question could even be re-formulated in a more
general way as follows: are mobile elements negative or
positive? And the answer is they are both! Being inser-
tional mutagens, mobile elements (and these include
prokaryotic elements, retrotransposons, ERVs, etc.) are
positive at the level of evolution, by generating diversity.
In this respect it is remarkable that mobile elements are in
general strongly repressed in the somatic cells, but repres-
sion is released to some extent in the germline, and this is
true from Drosophila to mammals. And the germline is
the right place for mutations to occur and generate variant
offspring, which then will be subjected to Darwinian
selection. But clearly mutations by insertion can be dele-
terious, and the best example is related to the insertional
mutagenesis produced at the somatic cell level by simple
oncogenic retroviruses, which can trigger tumors just in
this way. And in Drosophila, the I retrotransposon can
even induce embryonic lethality by excess retrotransposi-
tion. But of course mutations by insertion are not the sole
possible effects of RVs and ERVs that indeed encode viral
proteins which per se can have biological effects. These can
be positive -the syncytin case- and they may be negative -
the tumor case, via inhibition of immune surveillance.
AS: Your group is mainly focusing on 
endogenous retroviruses. What are your future 
directions/thoughts?
TH: The refined study of ERVs taught us and will continue
to teach us a lot on infectious retroviruses. This is expected
because both are remarkably similar, which is consistent
as they have common origins, but they have also a few dif-
ferences which, if studied in detail and with perseverance,
reveal important properties of both elements. An example
of that arose in the course of our study of the primate and
rodent syncytins. We found that all of them were indeed
functional envelope proteins, that is, they were fusogenic,
but we found that some of them were no longer immuno-
suppressive. This singularity actually allowed us to pre-
cisely map the domain responsible for this activity and to
find mutations for specifically knocking-down this func-
tion without altering the « mechanical » property of the
fusogenic envelope. This disjunction between the canoni-
cal fusion function of retroviral envelopes and the -often
ignored- immunosuppressive function, then allowed us
to show that the latter is indeed essential for viral replica-
tion and propagation in an immunocompetent host. And,
finally, this was rendered possible via the analysis of ERV
envelopes captured by ancestral hosts 40 My ago! So we
are now investigating this function in detail, in relation
with placenta formation for syncytins, inhibition of
tumor immunosurveillance for endogenous retroviruses,
and viremia for infectious retroviruses. We are also pres-
ently doing research on modified retroviral envelope pro-
teins to tentatively derive « optimized » antigens, and have
already obtained encouraging results on a veterinary vac-
cine.
AS: How do you explain that only a few groups 
are interested in ERVs?
TH: I think that it is a question of fashion. And to be frank,
it is much easier to get grants for HIV than for ERVs!
Although I have to admit that my research has always
been strongly supported by the CNRS, as well as by charity
associations fighting against cancer, both of which I
warmly thank. Also one has to acknowledge that if so
much has been discovered on HIV, it is thanks to the very
fundamental and in-depth virological studies that had
been performed for so many years on ALV, MLV and other
animal retroviruses; and I would like to add the ERVs to
this list! In this respect, I think it is not useless to alwaysPublish with BioMed Central    and   every 
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recall that fundamental science is most probably the best
way to be able in the long run to develop innovative ther-
apeutics and vaccine strategies which will work, and that
it has to be financially supported! But I think that most
modern countries have now understood that research is
essential for development, so I am confident that resolute
individuals will always have the means to find their way.
AS: What would you say to young students 
wanting to start out in research?
TH: Just do it! In fact it is a pity that a large fraction of the
students are no longer interested in science. There are
many possible reasons for that, maybe not enough science
taught in school, insufficient popularization, and lack of
social -and financial!- acknowledgment in our country.
Many graduate students, and quite often the most gifted
ones turn to business schools, and are lost to research.
Maybe one positive outcome of the present financial crisis
will be to re-direct students to science, but this will take
time!
It is also our task to convince young people that scientific
research is not so difficult, that science is one of the most
complete forms of art; and if it requires a strong technical
basis and intellectual rigor, it also leaves a great deal to
intuition, promotes a sense of beauty and allows entry
into the greatest terra incognita remaining to be explored
by the new generations, all activities that are most proba-
bly deeply encoded in our genes of evolved primates!
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